Finally, they demonstrated that the HDAC inhibitor panobinostat (LBH589, used in clinical trials for lymphoma and myeloma) was able to increase the acetylation level of endogenous STAT3 in a dose-dependent manner. The gene discussed is HDAC9; the disease is lymphoma.